


GreenLight XPS™ versus TURP:

Shorter Length of Stay and Cost Saving to the NHS¹⁻⁵



Savings in length of stay of up to two days can be achieved with GreenLight XPSTM vs TURP^{1,2}





National average Length of Stay (LOS) for TURP vs GreenLight XPS™ used at a high-volume GreenLight™ centre*1




Over a 50% reduction in bed days with GreenLight XPSTM vs TURP *1,3-5

AVERAGE NUMBER
OF BPH PROCEDURES PER TRUST:




Average number of bed days per trust with GreenLight XPS™ vs. TURP¹,³-5



*Data reported from 2 separate non-comparative analyses (HES data and Goliath study data)



Significant cost savings in day-case BPH procedures with GreenLight XPSTM vs TURP*2



GreenLight XPSTM 1-5



✓ TRUE DAY-CASE PROCEDURE



✓ EQUALLY EFFECTIVE IN NON-HIGH-RISK BPH PATIENTS COMPARED TO BOTH M-TURP & B-TURP



SUBSTANTIAL NHS COST SAVINGS

- 1. GreenLight HES data: "Average length of stay from April to December 2015 from NHS Hospital Episode Statistics, accessed via Health IQ VANTAGE on 5 May 2016. Contains public sector information licensed under the Open Government Licence v3.0
- 2. Boston Scientific Data on File
- 3. Bachmann A, Tubaro A, Barber N, *et al.*180-W XPS GreenLight Laser Vaporisation Versus Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 6 Month Safety and Efficacy Results of a European Multi-Centre Randomised Trial The GOLIATH Study. Euro Urol. May 2014; 65(5): 931-942.
- 4. Bachmann A, Tubaro A, Barber N, *et al.* A European Multicenter Randomized Noninferiority Trial Comparing 180-W GreenLight-XPS Laser Vaporization and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 12 Month Results of the GOLIATH Study. J. Urol. 2015 Feb; 193(2):570-8.
- 5. Thomas JA, Tubaro A, Barber N, *et al.* A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. Eur Urol. 2016 Jan;69(1):94-102.

URO-395109-AA May2016 DINURO2222EA

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Information for the use only in countries with applicable health authority product registrations.